Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?

Jans et al., Cells 2020, 9:9, 2100, doi:10.3390/cells9092100
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 110 treatments. c19ivm.org
Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2. Cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, Venezuelan equine encephalitis virus, Chikungunya virus, Pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19).
Reviews covering ivermectin for COVID-19 include1-45.
Jans et al., 15 Sep 2020, peer-reviewed, 2 authors.
This PaperIvermectinAll
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
David A Jans, Kylie M Wagstaff
Cells, doi:10.3390/cells9092100
The small molecule macrocyclic lactone ivermectin, approved by the US Food and Drug Administration for parasitic infections, has received renewed attention in the last eight years due to its apparent exciting potential as an antiviral. It was identified in a high-throughput chemical screen as inhibiting recognition of the nuclear localizing Human Immunodeficiency Virus-1 (HIV-1) integrase protein by the host heterodimeric importin (IMP) α/β1 complex, and has since been shown to bind directly to IMPα to induce conformational changes that prevent its normal function in mediating nuclear import of key viral and host proteins. Excitingly, cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, Venezuelan equine encephalitis virus, Chikungunya virus, Pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Phase III human clinical trials have been completed for DENV, with >50 trials currently in progress worldwide for SARS-CoV-2. This mini-review discusses the case for ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2.
References
Alam, Murshed, Bhiuyan, Saber, Alam et al., A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline, Bangladesh Coll. Phys. Surg, doi:10.3329/jbcps.v38i0.47512
Arshad, Pertinez, Box, Tatham, Rajoli et al., Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived From Their Established Human Pharmacokinetics, Clin. Pharm. Ther, doi:10.1002/cpt.1909
Atkinson, Audsley, Lieu, Marsh, Thomas et al., Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V, Sci. Rep, doi:10.1038/s41598-017-18742-8
Bennett, Zhao, Bosard, Imperiale, Role of a nuclear localization signal on the minor capsid proteins VP2 and VP3 in BKPyV nuclear entry, Virology, doi:10.1016/j.virol.2014.10.013
Bhatt, Gething, Brady, Messina, Farlow et al., The global distribution and burden of dengue, Nature
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2016638
Brady, Gething, Bhatt, Messina, Brownstein et al., Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus, PLoS Negl. Trop. Dis, doi:10.1371/journal.pntd.0001760
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res, doi:10.1016/j.antiviral.2020.104787
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: Potential target for anti-virals?, Antivir. Res, doi:10.1016/j.antiviral.2012.06.008
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N. Engl. J. Med
Changeux, Amoura, Rey, Miyara, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, Comptes Rendus Biol, doi:10.5802/crbiol.8
Ci, Li, Yu, Zhang, Yu et al., Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam. Clin. Pharmacol, doi:10.1111/j.1472-8206.2009.00684.x
Crump, Omura, Ivermectin, wonder drug from Japan: The human use perspective, Proc. Jpn. Acad, doi:10.2183/pjab.87.13
Crump, Omura, Ivermectin: Panacea for resource-poor communities?, Trends Parasitol
Foundation, The Nobel Prize in Medicine or Physiology
Fraser, Watanabe, Wang, Chan, Maher et al., A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection, J. Infect. Dis, doi:10.1093/infdis/jiu319
Frieman, Yount, Heise, Kopecky-Bromberg, Palese et al., Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane, J. Virol, doi:10.1128/JVI.01012-07
Fulcher, Jans, Regulation of nucleocytoplasmic trafficking of viral proteins; an integral role in pathogenesis ?, Biochem. Biophys. Acta Mol. Cell Res, doi:10.1016/j.bbamcr.2011.03.019
González Canga, Sahagún Prieto, Diez Liébana, Fernández Martínez, Sierra et al., The pharmacokinetics and interactions of ivermectin in humans-A mini-review, AAPSJ, doi:10.1208/s12248-007-9000-9
Gotz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci. Rep, doi:10.1038/srep23138
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J. Clin. Pharmacol, doi:10.1177/009127002401382731
Jans, Martin, Wagstaff, Inhibitors of nuclear transport, Curr. Opin. Cell Biol, doi:10.1016/j.ceb.2019.01.001
King, Tessier, Dodge, Weinberg, Mymryk, Lnhibition of human adenovirus replication by the importin α/β1 nuclear import inhibitor ivermectin, J. Virol, doi:10.1128/JVI.00710-20
Krause, Buisson, Bertrand, Corringer, Galzi et al., Lvermectin: A positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor, Mol. Pharmacol, doi:10.1124/mol.53.2.283
Kumar, Jeyaraman, Jain, Anudeep, A Wonder Drug in the Arsenal against COVID-19: Medication Evidence from Ivermectin, J. Adv. Med. Med. Res, doi:10.9734/jammr/2020/v32i1030512
Lopez-Denman, Russo, Wagstaff, White, Jans et al., Nucleocytoplasmic shuttling of the West Nile virus RNA-dependent RNA polymerase NS5 is critical to infection, Cell. Microbiol, doi:10.1111/cmi.12848
Loukas, Hotez, Chemotherapy of helminth infections
Lundberg, Pinkhan, Baer, Amaya, Narayan et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, Antivir. Res, doi:10.1016/j.antiviral.2013.10.004
Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of Pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antivir. Res, doi:10.1016/j.antiviral.2018.09.010
Mastrangelo, Pezzullo, De Burghgraeve, Kaptein, Pastorino et al., Lvermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug, J. Antimicrob. Chemother
Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: A systematic review and meta-analysis, J. Antimicrob. Chemother, doi:10.1093/jac/dkz524
Porat, Effects of Gossypol on the Motility of Mammalian Sperm, Mol. Reprod. Dev
Pryor, Rawlinson, Butcher, Barton, Waterhouse et al., Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha/beta-recognized nuclear localization sequences is integral to viral infection, Traffic, doi:10.1111/j.1600-0854.2007.00579.x
Rahman, Iqbal, Islam, Niaz, Hussain et al., Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients, Bangladesh Coll. Phys. Surg, doi:10.3329/jbcps.v38i0.47514
Schmith, Zhou, Lohmer, The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19, Clin. Pharm. Ther, doi:10.1002/cpt.1889
Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir. Res, doi:10.1016/j.antiviral.2013.06.002
Thomas, Lundberg, Pinkhan, Shechter, Debono et al., Identification of novel antivirals inhibiting recognition of Venezuelan equine encephalitis virus capsid protein by the Importin α/β1 heterodimer through high-throughput screening, Antivir. Res, doi:10.1016/j.antiviral.2018.01.007
Twum-Danso, Meredith, Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis, Trop. Med. Int. Health, doi:10.1046/j.1365-3156.2003.01091.x
Us Food, Administration, FDA Cautions against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial due to Risk of Heart Rhythm Problems
Varghese, Kaukinen, Glaesker, Bespalov, Hanski et al., Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir. Res, doi:10.1016/j.antiviral.2015.12.012
Wagstaff, Headey, Telwatte, Tyssen, Hearps et al., Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import, Cell. Microbiol, doi:10.1111/cmi.12953
Wagstaff, Rawlinson, Hearps, Jans, An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import, J. Biomol. Screen, doi:10.1177/1087057110390360
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J, doi:10.1042/BJ20120150
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Yamasmith, Saleh-Arong, Avirutnan, Angkasekwinai, Mairiang et al., Efficacy and Safety of Ivermectin against Dengue Infection: A Phase III, Randomized, Double-blind, Placebo-controlled Trial
Yang, Atkinson, Fraser, Wang, Maher et al., Novel Flavivirus Antiviral That Targets The Host Nuclear Transport Importin α/β1 Heterodimer, Cells, doi:10.3390/cells8030281
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antivir. Res, doi:10.1016/j.antiviral.2020.104760
Yang, Ye1, Zhu, Wang, Deng et al., Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets, Sci. Rep, doi:10.1038/srep17554
Yu, Chan, Gossypol as a male antifertility agent-Why studies should have been continued, Int. J. Androl, doi:10.1046/j.1365-2605.1998.00091.x
{ 'indexed': {'date-parts': [[2024, 5, 7]], 'date-time': '2024-05-07T11:18:41Z', 'timestamp': 1715080721755}, 'reference-count': 54, 'publisher': 'MDPI AG', 'issue': '9', 'license': [ { 'start': { 'date-parts': [[2020, 9, 15]], 'date-time': '2020-09-15T00:00:00Z', 'timestamp': 1600128000000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100000925', 'name': 'National Health and Medical Research Council', 'doi-asserted-by': 'publisher', 'award': ['Senior Principal Research Fellowship APP1002486/APP1103050']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>The small molecule macrocyclic lactone ivermectin, approved by the US Food and Drug ' 'Administration for parasitic infections, has received renewed attention in the last eight ' 'years due to its apparent exciting potential as an antiviral. It was identified in a ' 'high-throughput chemical screen as inhibiting recognition of the nuclear localizing Human ' 'Immunodeficiency Virus-1 (HIV-1) integrase protein by the host heterodimeric importin (IMP) ' 'α/β1 complex, and has since been shown to bind directly to IMPα to induce conformational ' 'changes that prevent its normal function in mediating nuclear import of key viral and host ' 'proteins. Excitingly, cell culture experiments show robust antiviral action towards HIV-1, ' 'dengue virus (DENV), Zika virus, West Nile virus, Venezuelan equine encephalitis virus, ' 'Chikungunya virus, Pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Phase III human ' 'clinical trials have been completed for DENV, with &gt;50 trials currently in progress ' 'worldwide for SARS-CoV-2. This mini-review discusses the case for ivermectin as a ' 'host-directed broad-spectrum antiviral agent for a range of viruses, including ' 'SARS-CoV-2.</jats:p>', 'DOI': '10.3390/cells9092100', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 15]], 'date-time': '2020-09-15T14:24:09Z', 'timestamp': 1600179849000}, 'page': '2100', 'source': 'Crossref', 'is-referenced-by-count': 52, 'title': 'Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?', 'prefix': '10.3390', 'volume': '9', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-5115-4745', 'authenticated-orcid': False, 'given': 'David A.', 'family': 'Jans', 'sequence': 'first', 'affiliation': []}, {'given': 'Kylie M.', 'family': 'Wagstaff', 'sequence': 'additional', 'affiliation': []}], 'member': '1968', 'published-online': {'date-parts': [[2020, 9, 15]]}, 'reference': [ {'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.2183/pjab.87.13'}, { 'key': 'ref2', 'unstructured': 'The Nobel Prize in Medicine or ' 'Physiologyhttps://www.nobelprize.org/prizes/medicine/2015/press-release'}, {'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1208/s12248-007-9000-9'}, { 'key': 'ref4', 'doi-asserted-by': 'crossref', 'first-page': '445', 'DOI': '10.1016/j.pt.2014.07.005', 'article-title': 'Ivermectin: Panacea for resource-poor communities?', 'volume': '30', 'author': 'Crump', 'year': '2014', 'journal-title': 'Trends Parasitol.'}, { 'key': 'ref5', 'unstructured': 'World Health Organization’s List of Essential Medicines 21st List ' '2019https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf'}, {'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.9734/jammr/2020/v32i1030512'}, {'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1042/BJ20120150'}, {'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.06.002'}, {'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.10.004'}, {'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep23138'}, {'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104760'}, {'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dks147'}, {'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-017-18742-8'}, {'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ceb.2019.01.001'}, {'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2015.12.012'}, {'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2018.01.007'}, {'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104787'}, {'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2018.09.010'}, {'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.virol.2014.10.013'}, {'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.00710-20'}, {'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.5802/crbiol.8'}, {'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1124/mol.53.2.283'}, {'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/009127002401382731'}, { 'key': 'ref24', 'series-title': 'Goodman & Gilman’s The Pharmacological Basis of Therapeutics', 'first-page': '1073', 'article-title': 'Chemotherapy of helminth infections', 'author': 'Loukas', 'year': '2006'}, {'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dkz524'}, {'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.1046/j.1365-3156.2003.01091.x'}, {'key': 'ref27', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbamcr.2011.03.019'}, {'key': 'ref28', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2012.06.008'}, {'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/cells8030281'}, {'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1600-0854.2007.00579.x'}, {'key': 'ref31', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiu319'}, {'key': 'ref32', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.01012-07'}, {'key': 'ref33', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep17554'}, {'key': 'ref34', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/1087057110390360'}, {'key': 'ref35', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cmi.12953'}, {'key': 'ref36', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cmi.12848'}, {'key': 'ref37', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1472-8206.2009.00684.x'}, {'key': 'ref38', 'doi-asserted-by': 'publisher', 'DOI': '10.1046/j.1365-2605.1998.00091.x'}, {'key': 'ref39', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/mrd.1080250414'}, {'key': 'ref40'}, {'key': 'ref41', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nature12060'}, {'key': 'ref42', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pntd.0001760'}, {'key': 'ref43', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2016638'}, {'key': 'ref44'}, {'key': 'ref45'}, {'key': 'ref46', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001282'}, {'key': 'ref47', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31022-9'}, {'key': 'ref48', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.1909'}, {'key': 'ref49', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.1889'}, { 'key': 'ref50', 'unstructured': 'Eurnekian Public Hospital Argentina’s IVERCAR Ivermectin & Carrageenan ' 'Study Shows Positive Results Targeting ' 'COVID-19https://www.trialsitenews.com/argentinas-ivercar-ivermectin-carrageenan-study-shows-positive-results-targeting-covid-19/'}, {'key': 'ref51', 'doi-asserted-by': 'publisher', 'DOI': '10.3329/jbcps.v38i0.47512'}, {'key': 'ref52', 'doi-asserted-by': 'publisher', 'DOI': '10.3329/jbcps.v38i0.47514'}, { 'key': 'ref53', 'unstructured': 'RM_270-2020-MINSAhttps://cdn.www.gob.pe/uploads/document/file/694719/RM_270-2020-MINSA.PDF'}, { 'key': 'ref54', 'unstructured': 'Ministerial Resolution No 259 from the Gobierno del Estate Plurinacional ' 'de Bolivia Misterio de ' 'Saludhttps://www.minsalud.gob.bo/component/jdownloads/send/27-comunicado-oficial/425-resolucion-ministerial-n-0259'}], 'container-title': 'Cells', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.mdpi.com/2073-4409/9/9/2100/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2020, 9, 16]], 'date-time': '2020-09-16T00:29:09Z', 'timestamp': 1600216149000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.mdpi.com/2073-4409/9/9/2100'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9, 15]]}, 'references-count': 54, 'journal-issue': {'issue': '9', 'published-online': {'date-parts': [[2020, 9]]}}, 'alternative-id': ['cells9092100'], 'URL': 'http://dx.doi.org/10.3390/cells9092100', 'relation': {}, 'ISSN': ['2073-4409'], 'subject': [], 'container-title-short': 'Cells', 'published': {'date-parts': [[2020, 9, 15]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit